HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICCVAM

This article was originally published in The Rose Sheet

Executive Summary

Federal agencies' responses to recommendations on non-animal test methods for assessing allergic contact dermatitis hazard potential of chemicals is now available, reports the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods. Two test methods recommended to the agencies by ICCVAM were the murine local lymph node assay (LLNA), which uses 20% fewer animals than the original protocol recommended in 1999, and the reduced murine local lymph node assay (rLLNA), which can reduce animal use by 40% compared with the standard LLNA. ICCVAM gave agencies - including FDA, the EPA and the Consumer Product Safety Commission - 180 days to respond to its favorable recommendation for the tests, which comes after consideration of a peer review panel report, public comments and feedback from its Scientific Advisory Committee on Alternative Toxicological Methods (1"The Rose Sheet" Oct. 19, 2009, In Brief)
Advertisement

Related Content

ICCVAM vouches for rLLNA
Advertisement
UsernamePublicRestriction

Register

RS016928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel